A cannabis therapy research company have found that studies on cannabis sativa extracts show promising results as an additional treatment for COVID-19.
Pathway RX collaborated with the University of Lethbridge to conduct the large-scale analysis and animal model.
Doctors Igor (CEO of Pathway RX) and Olga Kovalchuk, both University of Lethbridge biology professors, stated that their study is “crucial for the future analysis of the effects of medical cannabis on COVID-19.”
The study focused on how certain cannabis extracts affected ACE2 and TMPRSS2 proteins. These proteins are embedded into the cellular membrane and represent a key gateway for the COVID-19 virus to enter host cells.
Using cannabis sativa extracts, the researchers were able to modulate the levels of these enzymes.
They reported that initial findings from their study showed that 13 C. sativa extracts, that are high in the anti-inflammatory CBD (cannabinoid cannabidiol), can modulate ACE2 expression in COVID-19 target tissues and down-regulate TMPRSS2.
The results demonstrate that these high-CBD C. sativa lines have the potential to become a useful and safe addition to COVID-19 treatment, according to the researchers. They propose that they could be included in the form of mouthwash or similar products as a preventative treatment for the virus.
“Given the current dire and rapidly developing epidemiological situation, every possible therapeutic opportunity and avenue needs to be considered,” Kovalchuk stated. “Our research team is actively pursuing partnerships to conduct clinical trials.”